Reclast (Zoledronic Acid) vs Evenity (Romosozumab): Cost and Access Head-to-Head

What Are These Two Drugs and How Do They Work?

Zoledronic acid and romosozumab attack bone loss through completely different mechanisms. Zoledronic acid suppresses osteoclast activity, reducing bone breakdown. Romosozumab blocks sclerostin, which simultaneously increases bone formation and decreases resorption. That dual action is why romosozumab is classified as an anabolic agent even though it also carries some antiresorptive properties.

Zoledronic Acid (Reclast): Mechanism

Zoledronic acid belongs to the nitrogen-containing bisphosphonate class. After a single 5 mg IV infusion, the drug binds to hydroxyapatite on bone surfaces and is taken up by osteoclasts, where it inhibits farnesyl pyrophosphate synthase. This triggers osteoclast apoptosis and slows bone resorption for up to 12 months per dose. The FDA label for zoledronic acid lists postmenopausal osteoporosis, glucocorticoid-induced osteoporosis, and Paget disease among its approved indications.

Romosozumab (Evenity): Mechanism

Romosozumab is a humanized monoclonal IgG2 antibody that binds and inhibits sclerostin, a protein produced by osteocytes that normally brakes bone formation. Blocking sclerostin activates the Wnt signaling pathway, stimulating osteoblasts while also reducing RANKL-mediated osteoclast activity. The FDA approval announcement for Evenity (April 2019) notes the drug is indicated for postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture or multiple risk factors. Treatment is capped at 12 monthly injections because the anabolic effect diminishes after that window.

Key Efficacy Trials: HORIZON-PFT vs ARCH

Understanding the cost-access debate requires knowing what each drug actually delivers in fracture outcomes. The two key trials used different comparators, so a direct statistical comparison of their headline numbers is not valid. Still, both trials enrolled patients with severe postmenopausal osteoporosis and reported results that shaped current guidelines.

HORIZON-PFT (Zoledronic Acid)

The Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly Key Fracture Trial enrolled 7,765 postmenopausal women with osteoporosis. Published in the New England Journal of Medicine in 2007, the trial showed a 70% relative risk reduction in morphometric vertebral fractures (3.3% zoledronic acid vs 10.9% placebo at 3 years, P<0.001) and a 41% reduction in hip fractures. All-cause mortality was also 28% lower in the zoledronic acid group (P=0.01), a finding not replicated by most other osteoporosis drugs. The trial's full dataset on PubMed remains one of the most cited bisphosphonate studies in clinical practice.

ARCH (Romosozumab)

The Active-Controlled Fracture Study in Postmenopausal Women with Osteoporosis at High Risk enrolled 4,093 women and compared 12 months of romosozumab 210 mg monthly followed by alendronate against alendronate alone for 24 months total. Published in the New England Journal of Medicine in 2017, ARCH found that the romosozumab-to-alendronate sequence reduced new vertebral fractures by 48% compared with alendronate alone (6.2% vs 11.9%, P<0.001) at 24 months. Clinical fractures fell by 27% and hip fractures by 38% in the romosozumab sequence arm. However, serious cardiovascular events occurred in 2.5% of the romosozumab group vs 1.9% in the alendronate group (P=0.07), prompting the current FDA black box warning about myocardial infarction and stroke.

What the Trials Cannot Tell You

Neither trial directly compared zoledronic acid against romosozumab. The HORIZON-PFT comparator was placebo; the ARCH comparator was alendronate. Translating "70% vs placebo" and "48% vs alendronate" into a head-to-head ranking is not statistically sound. What the data do show: both drugs significantly reduce vertebral fracture risk in high-risk postmenopausal women, and the American Society for Bone and Mineral Research has outlined sequencing strategies to maximize long-term outcomes after romosozumab's 12-month course ends.

Cost Comparison: Zoledronic Acid vs Romosozumab

This is where the two drugs diverge most sharply for most patients.

Zoledronic Acid Pricing

Generic zoledronic acid 5 mg/100 mL solution has been available since 2015. Wholesale acquisition cost (WAC) for the generic runs roughly $300 to $500 per vial, though hospital outpatient and infusion center markups can push the patient-facing charge higher before insurance adjustments. GoodRx pricing data published in peer-reviewed pharmacoeconomic analyses places the average cost-effectiveness of zoledronic acid well below $50,000 per quality-adjusted life year gained, a threshold considered cost-effective by most U.S. Health economists. A 2019 JAMA Internal Medicine analysis of osteoporosis treatment costs found bisphosphonates remained the most cost-effective first-line agents across multiple fracture-risk categories.

Romosozumab Pricing

Evenity carries a WAC of approximately $1,825 per prefilled syringe. Because the dose is two 105 mg injections per month, the annual drug cost alone approaches $21,000 before administration fees. A 2020 cost-effectiveness analysis published in Osteoporosis International found romosozumab was cost-effective only in women aged 65 or older with a prior vertebral fracture and a 10-year FRAX hip fracture probability above roughly 3%, with an incremental cost-effectiveness ratio near $96,000 per QALY under base-case assumptions. Amgen offers a patient assistance program (Evenity Together), but eligibility requirements and income caps apply.

Head-to-Head Cost Summary

For a Medicare Part B patient receiving zoledronic acid in an outpatient infusion center, the 20% coinsurance on a $400 drug claim is roughly $80 out of pocket after meeting the Part B deductible. The same Medicare patient receiving monthly romosozumab injections faces coinsurance on a far larger allowed amount, and many Medicare Advantage plans require prior authorization and may apply step-edit requirements. CMS reimbursement data for HCPCS code J3489 (zoledronic acid) reflects the drug's lower cost basis relative to biologics billed under J-code J0897 (romosozumab).

Insurance Access and Prior Authorization

Zoledronic Acid Coverage

Zoledronic acid is almost universally covered. It sits on the preferred tier of most formularies because generics are available and the drug is administered in a clinical setting billable under Medicare Part B. Physicians rarely need to file a prior authorization for zoledronic acid when the diagnosis of osteoporosis with DXA-confirmed T-score at or below minus 2.5 is documented. The Endocrine Society's 2019 clinical practice guideline on postmenopausal osteoporosis lists bisphosphonates, including zoledronic acid, as first-line therapy for most patients.

Romosozumab Coverage and Step Therapy

Romosozumab typically requires prior authorization at every major commercial payer and at most Medicare Advantage plans. Common criteria include:

• DXA T-score at or below minus 2.5 at the spine or hip
• History of a fragility fracture (vertebral, hip, or multiple non-vertebral) or very high FRAX score
• Failure of or contraindication to at least one prior oral or IV bisphosphonate (step therapy)
• No recent myocardial infarction or stroke within the prior 12 months (per the black box warning)

The step-therapy requirement creates a practical sequencing pattern: many patients end up on a bisphosphonate first, then may qualify for romosozumab if bone density fails to respond or fractures occur despite therapy. The 2022 AACE/ACE Clinical Practice Guidelines for Diagnosis and Treatment of Postmenopausal Osteoporosis stratify patients as high or very high fracture risk and reserve anabolic agents including romosozumab for the very high-risk tier, which aligns with most payer coverage criteria.

Appeals and Peer-to-Peer Reviews

When romosozumab is denied, a peer-to-peer review between the prescribing physician and the payer's medical director can reverse the decision in a meaningful fraction of cases. Documenting prior fragility fractures, serial DXA scans showing progressive bone loss despite bisphosphonate use, and the cardiovascular screening performed to rule out recent MI or stroke strengthens the appeal. FDA guidance on prior authorization and step therapy does not mandate specific practices, leaving coverage decisions to payer discretion.

Administration: Infusion vs Injection

Zoledronic Acid Administration

A 5 mg dose is delivered as a 15-minute IV infusion once per year. Patients must be adequately hydrated before and after the infusion to reduce the risk of renal toxicity. Serum creatinine should be checked; zoledronic acid is contraindicated if creatinine clearance falls below 35 mL/min. The prescribing information also notes that calcium and vitamin D supplementation should be given concomitantly to prevent hypocalcemia. Post-infusion flu-like symptoms (fever, myalgia, arthralgia) occur in roughly 30% of patients after the first dose and are usually self-limiting within 72 hours.

The once-yearly schedule is a compliance advantage. Adherence to oral bisphosphonates (weekly or monthly tablets) drops sharply after the first year. A 2012 Osteoporosis International study (N=35,537) found that fewer than 40% of patients remained adherent to oral bisphosphonates at 12 months, whereas annual IV dosing removes that barrier entirely.

Romosozumab Administration

Romosozumab is given as two subcutaneous injections at separate sites on the same day, once monthly, for exactly 12 months. Injections may be administered by a healthcare provider or self-administered after training. The Evenity prescribing information requires that calcium and vitamin D be co-administered and that patients undergo cardiovascular risk screening before initiation. After the 12-month course ends, transition to an antiresorptive agent (most commonly a bisphosphonate) is required to preserve the bone density gains. Stopping romosozumab without sequential therapy leads to rapid bone loss.

Safety Profiles Side by Side

Zoledronic Acid Safety

The main safety concerns for long-term bisphosphonate use are osteonecrosis of the jaw (ONJ) and atypical femoral fractures (AFF). A 2014 JAMA Internal Medicine systematic review estimated the risk of ONJ at roughly 1 in 10,000 to 1 in 100,000 patient-years in non-oncology doses, and AFF at roughly 3 to 5 per 100,000 patient-years, rising with treatment duration beyond 5 years. Annual kidney function monitoring is recommended. The drug is not given during pregnancy (Category D) and is contraindicated in severe renal impairment.

Romosozumab Safety

The cardiovascular signal in ARCH (2.5% vs 1.9% serious CV events, P=0.07) was not seen in the earlier FRAME trial (placebo-controlled), but the FDA added the black box warning based on ARCH data. The FRAME trial (N=7,180, published in NEJM 2016) showed no significant cardiovascular imbalance vs placebo. Patients with a history of MI or stroke within the preceding year should not receive romosozumab per the label. ONJ and AFF have been reported rarely. Hypocalcemia is a known risk; pre-treatment calcium and vitamin D optimization is mandatory.

Which Patients Benefit Most from Each Drug?

Zoledronic Acid Is Typically First Choice When:

• The patient has osteoporosis (T-score at or below minus 2.5) without a recent major fragility fracture
• Oral bisphosphonate adherence has been poor or GI intolerance has been a problem
• Renal function is adequate (CrCl above 35 mL/min)
• The patient has a history of recent cardiovascular events that would contraindicate romosozumab
• Cost and insurance access are primary concerns
• The patient is in a low-to-high (not very high) fracture risk category per AACE 2022 guidelines

Romosozumab Is Typically Considered When:

• The patient has very high fracture risk: a recent vertebral or hip fracture, or multiple prior fragility fractures
• Bone density has continued to decline despite adequate bisphosphonate therapy
• The 10-year FRAX hip fracture probability exceeds 4.5% (a threshold referenced in several payer criteria and supported by the National Osteoporosis Foundation/AACE guidelines)
• No MI or stroke within the prior 12 months
• The patient or payer can cover the higher cost, or the patient qualifies for manufacturer assistance

The Sequence Question

Because romosozumab is anabolic and bisphosphonates are antiresorptive, the romosozumab-to-bisphosphonate sequence used in ARCH maximizes total bone density gain. Starting with a bisphosphonate and then adding romosozumab may blunt the anabolic signal, a phenomenon observed in the STRUCTURE trial (N=436, JBMR 2017), which found larger BMD gains at the femoral neck when romosozumab followed teriparatide rather than bisphosphonate therapy. Most patients in clinical practice have already received a bisphosphonate before romosozumab is considered, and ARCH still showed significant fracture reduction even in that context.

Practical Access Steps for Clinicians

Getting romosozumab approved takes preparation. Gathering the following before submitting a prior authorization reduces denial rates:

• Current DXA report with T-scores at lumbar spine and total hip
• FRAX calculation with BMD input
• Documentation of any prior fragility fracture (radiology report or ICD-10 coding)
• Evidence of prior bisphosphonate trial (fill history or prescriptions) or documented reason for contraindication
• A recent (within 12 months) cardiovascular history confirming no MI or stroke
• Calcium and 25-OH vitamin D levels showing optimization or a supplementation plan

For zoledronic acid, a DXA confirming osteoporosis and the referral order for the infusion center or hospital outpatient department are typically sufficient. Medicare's Local Coverage Determination for IV bisphosphonate infusions specifies covered diagnoses and documentation requirements by MAC jurisdiction.

Monitoring After Treatment

After Zoledronic Acid

Repeat DXA is recommended 1 to 2 years after initiation to confirm response. The American College of Rheumatology 2022 guideline on glucocorticoid-induced osteoporosis notes that a bone mineral density increase of 3% to 6% at the lumbar spine is a typical response at 1 year. If BMD is stable or improving after 3 annual doses, a bisphosphonate holiday of 3 to 5 years may be considered in lower-risk patients per FDA drug safety communications on bisphosphonate duration.

After Romosozumab

After the 12-month course, DXA and bone turnover markers (procollagen type I N-terminal propeptide, P1NP; and C-telopeptide, CTX) should be assessed before transitioning. Zoledronic acid is the most common sequential agent. A 2021 JBMR analysis confirmed that BMD gains achieved with romosozumab are largely maintained when followed by zoledronic acid at 12 months post-transition. Skipping the sequential antiresorptive leads to rapid reversal of BMD gains and is considered a prescribing error under current guidelines.